Therapy Areas: Vaccines
Diamyd Medical reports positive results from follow-up of diabetes vaccine trial
16 June 2021 -

Diamyd Medical AB (Nasdaq First North Growth:DMYDB), a developer of precision medicine therapies for type 1 diabetes, reported on Wednesday that a longer term follow-up of participants in the DIAGNODE-2 trial of its diabetes vaccine Diamyd indicated a continuing effect from the treatment.

Actively treated individuals carrying the genetically defined haplotype HLA DR3-DQ2 followed their expected trajectory from 15 to 24 months, showing no indication of diminishing treatment effect compared to their progression up to to 15 months, Diamyd said. Additionally, there was no difference in adverse events between actively treated and placebo treated individuals at 24 months.

The vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.

Login
Username:

Password: